The potential therapeutic effects of THC on Alzheimer's disease.

  title={The potential therapeutic effects of THC on Alzheimer's disease.},
  author={Chuanhai Cao and Yaqiong Li and Hui Liu and Ge Bai and Jonathan Mayl and Xiaoyang Lin and Kyle J Sutherland and Neel R Nabar and Jianfeng Cai},
  journal={Journal of Alzheimer's disease : JAD},
  volume={42 3},
The purpose of this study was to investigate the potential therapeutic qualities of Δ9-tetrahydrocannabinol (THC) with respect to slowing or halting the hallmark characteristics of Alzheimer's disease. N2a-variant amyloid-β protein precursor (AβPP) cells were incubated with THC and assayed for amyloid-β (Aβ) levels at the 6-, 24-, and 48-hour time marks. THC was also tested for synergy with caffeine, in respect to the reduction of the Aβ level in N2a/AβPPswe cells. THC was also tested to… 

Figures from this paper

Efficacy of Cannabinoids in a Pre-Clinical Drug-Screening Platform for Alzheimer’s Disease

Nine of the 11 cannabinoids assayed have the ability to protect cells in four distinct phenotypic neurodegeneration screening assays, including those using neurons that lack CB1 and CB2 receptors, showing that non-psychoactive cannabinoids are potential lead drug candidates for AD and other neuro degenerative diseases.

Potential and Limits of Cannabinoids in Alzheimer’s Disease Therapy

The present paper aims to summarize the potential and limitations of cannabinoids as therapeutics for AD, focusing on recent pre-clinical and clinical evidence.

Low-Dose Delta-9-Tetrahydrocannabinol as Beneficial Treatment for Aged APP/PS1 Mice

Treatment with THC at 0.2 and 0.02 mg/kg improved the spatial learning of aged APP/PS1 mice, suggesting low-dose THC is a safe and effective treatment for AD.

An ultra-low dose of Δ9-tetrahydrocannabinol improves Alzheimer’s Disease-related cognitive deficits

In this preliminary study, it is seen that a single injection of ULD-THC alleviated cognitive impairments of a mice model for AD, 5xFAD mice, which may establish the foundations for the development of a pharmaceutical preparation for the treatment of AD patients.

An Ultra-Low Dose of ∆9-Tetrahydrocannabinol Alleviates Alzheimer’s Disease-Related Cognitive Impairments and Modulates TrkB Receptor Expression in a 5XFAD Mouse Model

It is shown that a single injection of ULD-THC alleviated cognitive impairments in 6- and 12-month-old 5xFAD mice, demonstrating for the first time the beneficial effects of a single ultra-low dose of THC in a mouse model of AD after disease onset.

Therapeutic properties of multi-cannabinoid treatment strategies for Alzheimer’s disease

Treatment of AD using a multi-cannabinoid strategy (such as whole plant cannabis extracts or particular CBD:THC combinations) may be more efficacious compared to cannabinoid isolate treatment strategies, and it is pertinent that future in vivo and clinical investigations consider sex effects.

CB2 Cannabinoid Receptor As Potential Target against Alzheimer's Disease

Accumulated evidence suggests a role for CB2 receptors in Alzheimer's disease (AD) and indicates their potential as a therapeutic target against this neurodegenerative disease.

Cannabinoid pharmacology and its therapeutic uses in Alzheimer’s disease

The potential neuroprotective ability of natural cannabinoids, such as CBD and THC, has increased the interest of research groups in studies targeting endocannabinoids, and CBD targeting AD has been investigated recently.

Cannabinoid Receptor 2 Participates in Amyloid-β Processing in a Mouse Model of Alzheimer's Disease but Plays a Minor Role in the Therapeutic Properties of a Cannabis-Based Medicine.

Findings suggest a minor role for the CB2 receptor in the therapeutic effect of the cannabis-based medicine in AβPP/PS1 mice, but also constitute evidence of a link between CB2 receptors and Aβ processing.

Attenuation of Oxidative Stress by Cannabinoids and Cannabis Extracts in Differentiated Neuronal Cells

The preliminary results demonstrated that cannabis extracts and phytocannabinoids have a promising potential as antioxidants, which can be further investigated to develop novel pharmaceuticals targeting oxidative stress therapy.



Alzheimer's disease; taking the edge off with cannabinoids?

Cannabinoids offer a multi‐faceted approach for the treatment of Alzheimer's disease by providing neuroprotection and reducing neuroinflammation, whilst simultaneously supporting the brain's intrinsic repair mechanisms by augmenting neurotrophin expression and enhancing neurogenesis.

Cannabidiol and Other Cannabinoids Reduce Microglial Activation In Vitro and In Vivo: Relevance to Alzheimer's Disease

CBD is able to modulate microglial cell function in vitro and induce beneficial effects in an in vivo model of AD, and may represent a novel therapeutic approach for this neurological disease.

Prevention of Alzheimer's Disease Pathology by Cannabinoids: Neuroprotection Mediated by Blockade of Microglial Activation

It is shown that senile plaques in AD patients express cannabinoid receptors CB1 and CB2, together with markers of microglial activation, and that CB1-positive neurons, present in high numbers in control cases, are greatly reduced in areas of microgoo activation.

GSK-3α regulates production of Alzheimer's disease amyloid-β peptides

It is shown that therapeutic concentrations of lithium, a GSK-3 inhibitor, block the production of Aβ peptides by interfering with APP cleavage at the γ-secretase step, but do not inhibit Notch processing.

Cannabinoid receptors and endocannabinoids: role in neuroinflammatory and neurodegenerative disorders.

The plasticity of the endocannabinoid system during the aforementioned central nervous system disorders is discussed, as well as its dysregulation, both of which have opened the way to the use of either direct and indirect activators or blockers of CB₁ and CB⁂ receptors for the treatment of the symptoms or progression of these diseases.

Bioenergetics breakdown in Alzheimer's disease: targets for new therapies.

  • U. Saxena
  • Biology
    International journal of physiology, pathophysiology and pharmacology
  • 2011
A disease model based on known human and animal data with regards to breakdown in neuronal energy generation will be put together, which will integrate energy deficits as the cause of neuronal dysfunction and abeta peptide production culminating in catastrophic loss of cognitive functions.

Activation of glycogen synthase kinase-3 beta mediates β-amyloid induced neuritic damage in Alzheimer's disease

Molecular mechanisms, emerging etiological insights and models to test potential therapeutic interventions in Alzheimer's disease.

A potential therapeutic agent, vaccinia virus complement control protein (VCP), involved in modulating the complement system in AD is discussed, shown in in vitro studies to block the complement activation caused by the beta peptide.

Tetrahydrocurcumin confers protection against amyloid &bgr;-induced toxicity

It is shown that tetrahydrocurcumin (THC), a metabolite of curcumin, shows a protective effect against oligomeric amyloid-&bgr;-induced toxicity, and the antioxidant activity may contribute to its protective effect.